{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:10:27Z","timestamp":1791807027384,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.eururo.2018.06.024","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T03:14:48Z","timestamp":1531538088000},"page":"597-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations"],"prefix":"10.1016","volume":"74","author":[{"given":"Zachary","family":"Klaassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Villavicencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.06.024_bib0465","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0470","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1464-410X.2005.05249.x","article-title":"The economic consequences of prostate and bladder cancer in the UK","volume":"95","author":"Sangar","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0475","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2018.06.024_bib0480","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0485","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2017.10.019","article-title":"It's all about the perspective: removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer\u2014a competing risks analysis","volume":"36","author":"Ferguson","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0495","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0500","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0505","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.juro.2012.11.120","article-title":"Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review","volume":"189","author":"Roupret","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0510","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/S1569-9056(16)60394-9","article-title":"New pathological features predicting prognosis of early-invasive urothelial carcinoma: quantitative substaging and tumour invasion pattern should assist WHO 1973 grading classification in predicting cancer-specific survival of stage pT1 bladder cancer","volume":"15","author":"Breyer","year":"2016","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2018.06.024_bib0515","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrurol.2016.126","article-title":"The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder","volume":"13","author":"Mathieu","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0520","series-title":"EAU guidelines: non-muscle-invasive bladder cancer","author":"Babjuk","year":"2018"},{"key":"10.1016\/j.eururo.2018.06.024_bib0525","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0530","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0535","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudjonsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0540","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0545","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5489\/cuaj.3143","article-title":"Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta","volume":"10","author":"Gotto","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2018.06.024_bib0550","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0555","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10147-016-1048-z","article-title":"Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study","volume":"22","author":"Kamiya","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2018.06.024_bib0560","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.13265","article-title":"Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series","volume":"117","author":"Gendy","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0565","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/21681805.2017.1303846","article-title":"Second-look resection for primary stage T1 bladder cancer: a population-based study","volume":"51","author":"Patschan","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0570","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0302-2838(03)00040-X","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumours","volume":"43","author":"Miladi","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0575","doi-asserted-by":"crossref","unstructured":"Naselli A, Hurle R, Paparella S, et al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2016.12.011.","DOI":"10.1016\/j.euf.2016.12.011"},{"key":"10.1016\/j.eururo.2018.06.024_bib0580","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0585","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Guerin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0590","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0595","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0600","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1002\/cncr.27587","article-title":"The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?","volume":"118","author":"Thomas","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.06.024_bib0605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0610","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0615","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0620","first-page":"CD001986","article-title":"Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer","volume":"4","author":"Shelley","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2018.06.024_bib0625","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0630","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.06.024_bib0635","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0640","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0645","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0650","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0655","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0660","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0665","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0670","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2013.10.016","article-title":"Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer","volume":"65","author":"Kamat","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0675","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.juro.2007.01.031","article-title":"Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer","volume":"177","author":"Lerner","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0680","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0685","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-150016","article-title":"Development of systemic and topical drugs to treat non-muscle invasive bladder cancer","volume":"1","author":"Jarow","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2018.06.024_bib0690","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.06.024_bib0695","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urolonc.2014.02.020","article-title":"BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0700","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0705","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2018.06.024_bib0710","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0715","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0720","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bju.12245","article-title":"Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy","volume":"113","author":"Ark","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0725","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0730","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.urology.2009.05.092","article-title":"Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer","volume":"74","author":"Guzzo","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.06.024_bib0735","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0740","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-410X.2012.11391.x","article-title":"Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection","volume":"112","author":"Sternberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0745","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0750","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.urolonc.2011.07.009","article-title":"Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis","volume":"31","author":"Canter","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0755","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bju.12742","article-title":"Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study","volume":"115","author":"Santos","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0760","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1464-410X.2005.05287.x","article-title":"Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy","volume":"95","author":"Wiesner","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0765","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0770","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MOU.0000000000000089","article-title":"Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer","volume":"24","author":"Porten","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0775","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.urolonc.2014.10.001","article-title":"Contemporary bladder cancer: variant histology may be a significant driver of disease","volume":"33","author":"Monn","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0780","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0785","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cncr.22756","article-title":"Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients","volume":"110","author":"Kamat","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.06.024_bib0790","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.urolonc.2014.01.020","article-title":"Micropapillary bladder cancer: current treatment patterns and review of the literature","volume":"32","author":"Willis","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0795","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.06.024_bib0800","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2018.06.024_bib0805","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0810","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","article-title":"Sequential bacillus Calmette-Guerin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes","volume":"195","author":"Gan","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0815","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0820","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0825","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0830","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urolonc.2016.08.017","article-title":"A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy\u2014a single-institution experience","volume":"35","author":"Yang","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0835","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0840","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00345-016-1856-9","article-title":"Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy?","volume":"35","author":"Golabek","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0845","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0850","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2010.09572.x","article-title":"Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment","volume":"107","author":"Kakiashvili","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0855","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00345-012-0996-9","article-title":"Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder","volume":"31","author":"Kluth","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0860","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0865","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/B:UROL.0000032688.37789.7c","article-title":"T1G3 bladder cancer\u2014indications for early cystectomy","volume":"36","author":"Masood","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0870","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0875","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0880","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.urology.2007.10.041","article-title":"Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy","volume":"71","author":"Gupta","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.06.024_bib0885","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11255-011-9941-x","article-title":"T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy","volume":"43","author":"De Berardinis","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0890","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.juro.2013.01.089","article-title":"Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder","volume":"190","author":"Kluth","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib1000","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0895","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1464-410X.2011.10462.x","article-title":"Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?","volume":"109","author":"Segal","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0900","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.juro.2007.05.054","article-title":"The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer","volume":"178","author":"Divrik","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0905","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1464-410X.2006.06145.x","article-title":"A re-staging transurethral resection predicts early progression of superficial bladder cancer","volume":"97","author":"Herr","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.06.024_bib0910","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)65168-3","article-title":"Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression","volume":"167","author":"Holmang","year":"2002","journal-title":"J Urol\u2013"},{"key":"10.1016\/j.eururo.2018.06.024_bib0915","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.024_bib0920","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T13:49:19Z","timestamp":1717249759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818304494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0302283818304494"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}